Follow
Cora N. Sternberg
Cora N. Sternberg
Clinical Director, Englander Institute for Precision Medicine, Professor of Medicine, Weill Cornell
Verified email at med.cornell.edu - Homepage
Title
Cited by
Cited by
Year
Increased survival with enzalutamide in prostate cancer after chemotherapy
HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ...
New England Journal of Medicine 367 (13), 1187-1197, 2012
52132012
Abiraterone and increased survival in metastatic prostate cancer
JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ...
New England Journal of Medicine 364 (21), 1995-2005, 2011
50512011
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
33582014
Pembrolizumab as second-line therapy for advanced urothelial carcinoma
J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ...
New England Journal of Medicine 376 (11), 1015-1026, 2017
32482017
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
CN Sternberg, ID Davis, J Mardiak, C Szczylik, E Lee, J Wagstaff, ...
Journal of clinical oncology 28 (6), 1061-1068, 2010
30332010
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical …
HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ...
Journal of clinical oncology 26 (7), 1148-1159, 2008
24352008
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
M Bolla, L Collette, L Blank, P Warde, JB Dubois, RO Mirimanoff, ...
The Lancet 360 (9327), 103-108, 2002
21852002
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ...
New England Journal of Medicine 369 (8), 722-731, 2013
21052013
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
M Bolla, D Gonzalez, P Warde, JB Dubois, RO Mirimanoff, G Storme, ...
New England Journal of Medicine 337 (5), 295-300, 1997
18521997
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo …
K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ...
The lancet oncology 13 (10), 983-992, 2012
16992012
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall …
CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ...
The Lancet Oncology 16 (2), 152-160, 2015
15602015
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402-1418, 2016
13512016
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open …
A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ...
The Lancet 387 (10018), 545-557, 2016
12002016
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium
JL Gabrilove, A Jakubowski, H Scher, C Sternberg, G Wong, J Grous, ...
New England Journal of Medicine 318 (22), 1414-1422, 1988
11471988
Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer
M Hussain, K Fizazi, F Saad, P Rathenborg, N Shore, U Ferreira, ...
New England Journal of Medicine 378 (26), 2465-2474, 2018
10872018
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
M Bolla, G Van Tienhoven, P Warde, JB Dubois, RO Mirimanoff, G Storme, ...
The lancet oncology 11 (11), 1066-1073, 2010
10832010
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ...
New England Journal of Medicine 383 (13), 1218-1230, 2020
10762020
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ...
The lancet oncology 17 (7), 917-927, 2016
10492016
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
M Bolla, H van Poppel, B Tombal, K Vekemans, L Da Pozzo, ...
The Lancet 380 (9858), 2018-2027, 2012
9152012
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
859*2018
The system can't perform the operation now. Try again later.
Articles 1–20